Sirtex Medical Inc. Announces 33 Percent Dose Sales Growth of SIR-Spheres® microspheres in Fourth Quarter
07 Julho 2014 - 11:00AM
Business Wire
Forty Consecutive Quarters of Dose Sales Growth
Globally
Sirtex Medical Inc., a subsidiary of Sirtex
Medical Limited (ASX:SRX), a leading manufacturer of targeted,
innovative liver cancer therapies, announced dose sales of
SIR-Spheres® microspheres grew 33 percent on a unit basis in the
Americas region for the quarter ending June 30, 2014, compared to
the previous corresponding period.
“Our dedication to building a team focused on a
comprehensive, multidisciplinary approach to ensure optimal patient
care has resulted in an outstanding performance by the Americas
region,” said Mike Mangano, president of Sirtex Medical, Inc.
“Adoption rates for this very important treatment option for
patients continue to grow as we anticipate the results of our
landmark clinical study SIRFLOX in 2015.”
Globally, Sirtex reported that dose sales of
SIR-Spheres microspheres grew 27.1 percent during the same period.
Gilman Wong, Sirtex CEO, said, “The successful implementation of
our business strategy with appropriate investment by the company in
sales and marketing, manufacturing, clinical studies and research
should ensure Sirtex achieves its full potential.”
In the coming year, the Americas region will
continue to focus on patient and physician education and expansion
strategies into other regions supported by an emphasis on the
company’s clinical studies as well as training and marketing
efforts.
For more information, visit www.Sirtex.com or
find the latest updates on the SIR-Spheres microspheres Facebook
page (www.Facebook.com/SIRSpheresmicrospheres).
About Selective Internal Radiation Therapy
using SIR-Spheres microspheres
Selective Internal Radiation Therapy (SIRT),
also known as radioembolization, is a proven technology for
inoperable liver cancer that delivers doses of radiation directly
to the site of tumors. In a minimally invasive treatment, millions
of radioactive SIR-Spheres microspheres are infused via a catheter
into the liver where they selectively target liver tumors with a
dose of internal radiation up to 40 times higher than conventional
radiotherapy, while sparing healthy tissue.
Clinical studies have confirmed that patients
with metastatic colorectal cancer treated with SIR-Spheres
microspheres have response rates higher than with other forms of
treatment, resulting in increased life expectancy, greater periods
without tumor activity and improved quality of life. SIRT has been
found to shrink liver tumors more than chemotherapy alone.
In the U.S., SIR-Spheres microspheres are
indicated for the treatment of unresectable metastatic liver tumors
from primary colorectal cancer with adjuvant intra-hepatic artery
chemotherapy (IHAC) of FUDR (Floxuridine). SIR-Spheres microspheres
are approved for use in Argentina, Brazil, Australia, the European
Union and several countries in Asia for the treatment of
unresectable liver tumors.
Available at more than 700 treatment centers,
over 40,000 doses of SIR-Spheres microspheres have been supplied
worldwide.
For more information, visit www.sirtex.com.
SIR-Spheres® is a registered trademark of
Sirtex SIR-Spheres Pty Ltd.
For SirtexElizabeth Romero,
919-457-0749elizabeth.romero@fleishman.com
Sierra Rutile (ASX:SRX)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Sierra Rutile (ASX:SRX)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
